Applied DNA Sciences, through its subsidiary Applied DNA Clinical Labs (ADCL), has expanded its clinical testing services for mpox, leading to a 37% surge in its stock price. The new service now includes detection of both Mpox Clade I and Clade II, aiming to bolster efforts to combat the rising mpox threat.